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TISSUE DECELLULARIZATION METHODS
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of and priority to co-pending U.S. Provisional
Patent
5

Application

No.

62/192,823,

filed

on

July

15,

2015,

entitled

"TISSUE

DECELLULARIZATION METHODS," the contents of which is incorporated by reference
herein in its entirety.

BACKGROUND

Decellularization technology offers the potential to attain tissue-specific scaffolds that
10

guide tissue regeneration following injury and/or disease. As such there exists a need for
improved decllularization methods for scaffold generation for tissue regeneration for
treatment of injury and/or disease.

SUMMARY

15

Provided herein are tissue decellularization methods, where the methods can include
the steps of obtaining a tissue sample from a subject to generate an ex vivo tissue sample;
exposing the ex vivo tissue sample to an apoptotic agent or apoptotic process; and washing
the ex vivo tissue sample in a hypertonic solution, a hypotonic solution, or a hypertonic
solution and a hypotonic solution. The tissue sample can be a peripheral nerve, a nucleus

20

pulposus, and/or a combination thereof.

The tissue sample can be a lung tissue. The

apoptotic agent is camptothecin, staurosporine, doxorubicin, or an analog thereof. The
apoptotic process can contain one or more freeze-thaw cycles. The concentration of the
apoptotic agent can range from about 5IJM to about 10 IJM. The concentration of the
apoptotic agent can be about 10 IJM. The concentration of the apoptotic agent can be about
25

5 IJM. The ex vivo tissue sample can be exposed to the apoptotic agent for about 2 days.
The tissue can be washed with a hypertonic solution. The hypertonic solution can be greater
than 1X buffered solution. The hypertonic solution is 4X saline. The tissue can be washed
with a hypotonic solution. The hypotonic solution can less than 1X buffered solution. The
hypotonic solution can be a 0.5X saline solution. The concentration the concentration of the

30

apoptotic agent can be about 5 IJM. The apoptotic agent can be camptothecin,
staurosporine, doxorubicin, or an analog thereof. The method can further include the step of
treating the tissue with DNAse for a period of time ranging from 30 minutes to 24 hours. The
step of washing can produce an acellular tissue product. The method can further include
step of adding an active agent to the acellular tissue product. The active agent can selected

35

from the group consisting of: a stem cell, nucleic acid, amino acid, peptide, polypeptide,
1
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antibody, aptamer, ribozyme, guide sequence for a ribozyme that inhibit translation or
transcription of essential tumor proteins and genes, hormone, immunomodulator, antipyretic,
anxiolytic, antipsychotic, analgesic, antispasmodic, anti-inflammatory, anti-histamine, antiinfective, a chemotherapeutic, or combinations thereof.
5

Also provided herein are acellular tissue products, where the acellular tissue product
can be formed by a method as described herein. The method can further include the step of
treating the tissue with DNAse for a period of time ranging from about 30 minutes to about
24 hours. The acellular tissue product can contain an active agent. The active agent can be
selected from the group consisting of: a stem cell, nucleic acid, amino acid, peptide,

10

polypeptide, antibody, aptamer, ribozyme, guide sequence for a ribozyme that inhibit
translation

or

transcription

of

essential

tumor

proteins

and

genes,

hormone,

immunomodulator, antipyretic, anxiolytic, antipsychotic, analgesic, antispasmodic, antiinflammatory, anti-histamine, anti-infective, a chemotherapeutic, or combinations thereof.
The acellular tissue product can be formulated for injection.
15

Also provided herein are methods including the step of administering an acellular
tissue product as provided herein to a subject in need thereof. The subject in need thereof
can have a spinal injury or disease, intervertebral disc degeneration, disease or trauma of
the lungs or liver, or volumetric muscle loss, peripheral nerve injury, amputation or spinal
degradation, osteoarthritis of the hip or knee, volumetric muscle loss, cirrhosis of the liver, or

20

otherwise requires partial or total organ replacement.

BRIEF DESCRIPTION OF THE DRAWINGS
Further aspects of the present disclosure will be readily appreciated upon review of
the detailed description of its various embodiments, described below, when taken in
25

conjunction with the accompanying drawings.
Fig. 1 shows one embodiment of a method for decellularization of a tissue sample.
Figs. 2A-2F show fluorescence micrographs of peripheral nerve with and without
apoptosis induction followed by washing with various regimens.
Fig. 3 shows a graph demonstrating DNA content of peripheral nerve under various

30

treatment regimens.
Fig. 4 shows a table demonstrating the quantification of DNA content shown in Fig. 3.
Figs. 5A-5C demonstrate fluorescence micrographs of nerve tissue labeled for cell or
basal lamina markers. For Figs. 5A and 58, the images are fresh nerve (top half) and
apoptosis decellularized nerve (bottom half). Fig. 5A was labeled for neurons (neurofilament,

35

green), 8chwann cells (8100, red), and nuclei (DAPI, blue). Fig. 58 shows cross-sections of

2
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the basal lamina stained for laminin (red). Fig. 5C shows a representative basal lamina
staining in nerve tissue decellularized according to a conventional detergent-based method.
Figs. 6A-6D demonstrate fluorescence micrographs of nucleus pulposus stained with
a nuclear stain (blue) and a chondroitin sulfate proteoglycan (CSPG) antibody (red).

5

Figs. 7A-7B demonstrate images of a carefully dissected motion segment of the
spine and an extracted nucleus pulposus.
Fig. 8 shows a graph demonstrating tibialis anterior muscle weight changes over time
in rats receiving detergent decellularized nerve graft, apoptosis decellularized nerve graft, or
an isograft of fresh nerve. This figure demonstrates that the apoptosis decellularization

10

method was not statistically different from isograft after 8 weeks, suggesting that the
apoptosis decellularization method has the potential to perform similarly to the clinical gold
standard and outperform traditional decellularization methods.
Figs. 9A-9C show fluorescence images demonstrating that the more gentle apoptosis
decellularization (Fig. 9C) process can result in less tissue disruption than the harsher

15

traditional decellularization methods which uses a water treatment to initiate decellularization
(Fig. 9B), and more comparable to fresh nerve (Fig. 9A).

DETAILED DESCRIPTION
Before the present disclosure is described in greater detail, it is to be understood that
20

this disclosure is not limited to particular embodiments described, and as such may, of
course, vary. It is also to be understood that the terminology used herein is for the purpose
of describing particular embodiments only, and is not intended to be limiting.
Where a range of values is provided, it is understood that each intervening value, to
the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between

25

the upper and lower limit of that range and any other stated or intervening value in that
stated range, is encompassed within the disclosure. The upper and lower limits of these
smaller ranges may independently be included in the smaller ranges and are also
encompassed within the disclosure, subject to any specifically excluded limit in the stated
range. Where the stated range includes one or both of the limits, ranges excluding either or

30

both of those included limits are also included in the disclosure.
Unless defined otherwise, all technical and scientific terms used herein have the
same meaning as commonly understood by one of ordinary skill in the art to which this
disclosure belongs. Although any methods and materials similar or equivalent to those
described herein can also be used in the practice or testing of the present disclosure, the

35

preferred methods and materials are now described.

3
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All publications and patents cited in this specification are herein incorporated by
reference as if each individual publication or patent were specifically and individually
indicated to be incorporated by reference and are incorporated herein by reference to
disclose and describe the methods and/or materials in connection with which the
5

publications are cited. The citation of any publication is for its disclosure prior to the filing
date and should not be construed as an admission that the present disclosure is not entitled
to antedate such publication by virtue of prior disclosure. Further, the dates of publication
provided could be different from the actual publication dates that may need to be
independently confirmed.

10

As will be apparent to those of skill in the art upon reading this disclosure, each of the
individual embodiments described and illustrated herein has discrete components and
features which may be readily separated from or combined with the features of any of the
other several embodiments without departing from the scope or spirit of the present
disclosure. Any recited method can be carried out in the order of events recited or in any

15

other order that is logically possible.
Embodiments of the present disclosure will employ, unless otherwise indicated,
techniques

of molecular biology,

microbiology,

nanotechnology,

organic chemistry,

biochemistry, botany and the like, which are within the skill of the art. Such techniques are
explained fully in the literature.

20

Definitions

As used herein, "about," "approximately," and the like, when used in connection with
a numerical variable, generally refers to the value of the variable and to all values of the
variable that are within the experimental error (e.g., within the 95% confidence interval for
the mean) or within ±10% of the indicated value, whichever is greater.

25

As used herein, "administering" refers to an administration that is oral, topical,
intravenous,
parenteral,

subcutaneous,
intra-arteriole,

transcutaneous,
intradermal,

transdermal,

intraventricular,

intramuscular,
intracranial,

intra-joint,

intraperitoneal,

intralesional, intranasal, rectal, vaginal, by inhalation or via an implanted reservoir. The term
"parenteral" includes but is not limited to, subcutaneous, intravenous, intramuscular, intra30

articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional, and intracranial
injections or infusion techniques.
As used interchangeably herein, "subject," "individual," or "patient," refers to a
vertebrate, preferably a mammal, more preferably a human. Mammals include, but are not
limited to, murines, simians, humans, farm animals, sport animals, and pets. The term "pet"

35

includes a dog, cat, guinea pig, mouse, rat, rabbit, ferret, and the like. The term farm animal
includes a horse, sheep, goat, chicken, pig, cow, donkey, llama, alpaca, turkey, and the like.

4
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As used herein, "control" is an alternative subject or sample used in an experiment
for comparison purposes and included to minimize or distinguish the effect of variables other
than an independent variable.
As used herein, "positive control" refers to a "control" that is designed to produce the
5

desired result, provided that all reagents are functioning properly and that the experiment is
properly conducted.
As used herein, "negative control" refers to a "control" that is designed to produce no
effect or result, provided that all reagents are functioning properly and that the experiment is
properly conducted. Other terms that are interchangeable with "negative control" include

10

"sham," "placebo," and "mock."
As used herein, "autologous" refers to being derived from the same subject that is the
recipient.
As used herein, "allograft" refers to a graft that is derived from one member of a
species and grafted in a genetically dissimilar member of the same species.

15

As used herein "xenograft" or "xenogeneic" refers to a substance or graft that is
derived from one member of a species and grafted or used in a member of a different
species.
As used herein, "autograft" refers to a graft that is derived from a subject and grafted
into the same subject from which the graft was derived.

20

As used herein, "allogeneic" refers to involving, derived from, or being individuals of
the same species that are sufficiently genetically different so as to interact with one another
antigenically.
As used herein, "donor" refers to a subject from which cells or tissues are derived.
As used herein, "hypertonic solution" refers to a solution that has a greater

25

concentration of solutes than the concentration of solutes inside of a cell.
As used herein, "hypotonic solution" refers to a solution that has a concentration of
solutes that is less than the concentration of solutes within a cell.
As used herein, "analog" refers to another compound, composition, or other
substance of matter that is considered comparable to the reference compound, composition,

30

or substance of matter and includes structural analogs and functional analogs.
Discussion
Decellularization technology offers the potential to attain tissue-specific scaffolds that
guide tissue regeneration following injury and/or disease. Most decellularization protocols
used in research and industry contain an initial cell lysis step in a hypotonic buffer, such as

35

water, followed by chemical solutions to remove cellular remnants. These harsh conditions
result in an undesirable broad dispersal of intracellular components, disruption of tissue
morphology, and removal of desired tissue elements.

5
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With that said, described herein are decellularization methods that do not require cell
lysis buffers or harsh chemicals. The decellularization methods described herein can include
inducing apoptosis in ex vivo tissue. The decellularization methods described herein can
effectively remove cellular components without having to rely on harsh conditions. In some
5

embodiments, the methods can effectively remove cellular components from peripheral
nerve and/or nucleus pulposus. In addition to reducing time, labor, and expense of
decellularization, some embodiments described herein can only need one step for inducing
apoptosis and one step for washing the cells.
Other compositions, compounds, methods, features, and advantages of the present

10

disclosure will be or become apparent to one having ordinary skill in the art upon
examination of the following drawings, detailed description, and examples. It is intended that
all such additional compositions, compounds, methods, features, and advantages be
included within this description, and be within the scope of the present disclosure.
Methods

15

Described herein are methods of decellularization that include inducing apoptosis in
an ex vivo tissue sample, where tissue wide apoptosis can be induced by exposing the
tissue to an apoptosis-inducing agent or apoptosis inducing process for a time period.
Induction of apoptosis in the ex vivo tissue sample can cause cell detachment from the
tissue extracellular matrix, degradation of intracellular DNA, RNA and proteins, and

20

allocation into apoptotic bodies, which can be removed using mild hypotonic and/or mild
hypertonic buffered solutions.
As shown in Fig. 1, the method 1000 can begin with obtaining a tissue sample from a
subject or other donor source 1010. The tissue can be autologous, xenogeneic, allogeneic,
or syngeneic. In some embodiments, the tissue can be obtained from anywhere in a subject.

25

In some embodiments, the tissue sample can be obtained from the periphery or spinal
column of a subject. In some embodiments, the tissue can be a peripheral nerve and/or
nucleus pulposus. In other embodiments, the tissue can be brain, spinal cord, heart, lung,
liver, muscle, cartilage, tendons, ligaments, menisci, stomach, intestine, pancreas, and/or
kidney. In further embodiments, the tissue is blood vessels, bone, and/or cornea.

30

After the tissue sample has been obtained, apoptosis can be induced 1020 in the ex
vivo tissue sample by exposing the ex vivo tissue sample to an apoptotic agent (i.e. a
compound and/or composition that induces apoptosis in a cell) for a time period. In some
embodiments, apoptosis can be induced by an apoptotic process (i.e. a process that can
include one or more steps that induces apoptosis). In some embodiments, the apoptotic

35

agent can be camptothecin, staurosporine, doxorubicin, and/or analogs thereof, or any other
agent or process that induces apoptosis. In other embodiments, the apoptotic agent could be
nitric oxide, hypoxia, pH, or hydrogen peroxide. In some embodiments where an apoptotic

6
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agent is used to induce apoptosis, the ex vivo tissue sample can be exposed to the apoptotic
agent for any length of time, including but not limited to, greater than about 1 hour, about 1
hour to about 10 days, about 1 hour to about 7 days, about 1 hour to about 4 days, about 1
hour to about 2 days, or about 1 hour to about 1 day. In some embodiments, the ex vivo
5

tissue sample can be exposed to camptothecin or analog thereof for 2 days. In some
embodiments, the tissue ex vivo tissue sample can be exposed to the apoptotic agent, such
as camptothecin, for about 1 day.
The ex vivo tissue sample can be exposed to a solution containing a concentration of
the apoptotic agent and/or to an apoptotic process. In some embodiments, the apoptotic

10

process does not use an apoptotic agent. In embodiments that employ an apoptotic agent,
the concentration of the apoptotic agent can range from about 1 nM to about 1 mM or
greater. In some embodiments, the concentration of the apoptotic agent can range from
about 1 IJM to about 1OOIJM.

In some embodiments, the concentration of the apoptotic

agent can be about 101JM. In some embodiments, the ex vivo tissue sample can be exposed
15

to 10 IJM of camptothecin or an analog thereof. In some embodiments, the ex vivo tissue
sample can be exposed to 10 IJM of camptothecin or an analog thereof for about 2 days. In
some embodiments, the concentration of the apoptotic agent can range from about 5 IJM to
about 10 IJM. In some embodiments, the concentration of the apoptotic agent is about 5 IJM.
In some embodiments, the ex vivo tissue sample can be exposed to 5 IJM camptothecin or

20

an analog thereof. In some embodiments, the ex vivo tissue sample can be exposed to 5 IJM
of camptothecin or an analog thereof for about 1 day.
In some embodiments, the apoptotic process includes exposure of the ex vivo tissue
to one or more freeze-thaw cycles to induce apoptosis.
After the ex vivo tissue sample can be exposed to an apoptotic agent or process for a

25

desired amount of time, the tissue sample can be washed 1030 with one or more washes
with one or more buffered solutions to facilitate cell removal. The ex vivo tissue sample can
be washed with one or more washes of a hypertonic buffered solution (i.e. greater than 1X
buffered solution). In some embodiments the number of washes ranges from one to six. In
some embodiments, the hypertonic solution can be a 1.01X-10X buffered solution. In some

30

embodiments, the concentration can be 4X with an intermediate 2X wash. The tissue sample
can be washed with one or more washes of a hypotonic buffered solution (i.e. less than 1X
buffered solution). In some embodiments, the hypotonic solution can be a 0.01X up to a
0.99X buffered solution. In embodiments, the buffered solution is a saline solution at the
given concentrations to result in a hypotonic or hypertonic solution. The starting saline

35

solution can be isotonic. The starting saline solution can have a formulation of 10X which is
diluted with water to attain various hypertonic washes. While not being bound to theory, it is
believed that DNA removal occurs under the hypotonic wash conditions, while protein
7
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removal occurs under the hypertonic wash conditions. Some embodiments employ only
hypertonic washes. Other embodiments employ only hypotonic washes. Yet further
embodiments employ both hypertonic and hypotonic washes.
In some embodiments, the method 1000 can also include an optional step of DNAse
5

treatment 1040. The DNAse treatment can occur after the wash(es) previously performed
1030. In some embodiments, the optional DNAse treatment 1040 is performed after
hypotonic washes 1030 were performed. In some embodiments where the optional DNAse
1040 treatment is performed, only hypertonic washes have been performed.

In

embodiments, the concentration of DNAse can range from 25 U/mL to 250 U/ mL. The
10

preferred concentration is 75 U/mL. The DNase can be any suitable DNase. The DNase
treatment can be performed at a temperature ranging from about 4 to about 3rC. The
preferred temperature is 25°C. It will be appreciated by those of ordinary skill in the art that
the temperature can be dependent on the temperature that the DNase has optimal activity.
The time period for the DNase treatment can range from about 30 minutes or less to 1, 2, 3,

15

4,5,6,7,8,9,10,11,12,24, or 36 hours or more. The treatment time can vary based on
tissue type, but in some embodiments the treatment time is 18-24 hours.
The method 1000 can produce an acellular tissue. The resulting acellular tissue can
be used as a scaffold substrate for three dimensional (3D) cell culture and tissue
engineering techniques. Further, the resulting acellular tissue can be delivered to a subject

20

in need thereof to facilitate the in vivo generation and/or regeneration of cells and tissues
within the subject. The resulting acellular tissue product can be formulated to be delivered to
a subject in need thereof by any suitable method of deliver, including but not limited to,
implantation or injection. The acellular tissue products can be enhanced by the addition of
one or more other agents or compounds to the acellular tissue product, including without

25

limitation other cells (e.g. stem cells or other progenitor cells), nucleic acids, amino acids,
peptides, polypeptides, antibodies, aptamers, ribozymes, guide sequences for ribozymes
that inhibit translation or transcription of essential tumor proteins and genes, hormones,
immunomodulators, antipyretics, anxiolytics, anti psychotics, analgesics, antispasmodics,
anti-inflammatories,

30

anti-histamines,

anti-infectives,

and chemotherapeutics.

In some

embodiments, the acellular tissue products can be co-administered with one or more other
agents or compounds, including without limitation other cells (e.g. stem cells or other
progenitor cells), nucleic acids, amino acids, peptides, polypeptides, antibodies, aptamers,
ribozymes, guide sequences for ribozymes that inhibit translation or transcription of essential
tumor proteins

35

antipsychotics,

and

genes,

analgesics,

hormones,

immunomodulators,

antispasmodics,

infectives, and chemotherapeutics.

8

antipyretics,

anti-inflammatories,

anxiolytics,

anti-histamines,

anti-

WO 2017/011653

PCT/US2016/042273

In some embodiments, any of the acellular tissue scaffolds described herein can be
administered to a subject in need thereof in the original form, as an injectable formulation, or
as other derivatives of the acellular tissue. In some embodiments, the subject in need
thereof has a peripheral nerve injury, spinal cord injury, spinal cord disease, amputation or
5

otherwise suffers from degradation of a component of the spine (e.g. intervertebral disc
degeneration). In other embodiments, the subject could have osteoarthritis of the hip or
knee, trauma to the lungs, volumetric muscle loss, cirrhosis of the liver, or otherwise requires
partial or total organ replacement.

EXAMPLES

10

Now having described the embodiments of the present disclosure, in general, the
following Examples describe some additional embodiments of the present disclosure. While
embodiments of the present disclosure are described in connection with the following
examples and the corresponding text and figures, there is no intent to limit embodiments of
15

the present disclosure to this description. On the contrary, the intent is to cover all
alternatives, modifications, and equivalents included within the spirit and scope of
embodiments of the present disclosure.
Example 1:
Peripheral nerves were harvested from Sprague Dawley rats and decellularized

20

according to an apoptosis-assisted protocol using 5 IJM camptothecin in non-supplemented
media at 3rC for 1 day. Tissue in media without camptothecin, an apoptotic agent, was
used as a control. Apoptotic agent treatment was succeeded by washes in saline buffered
solutions to optimize cell removal. Furthermore, the tissue was treated with 75 u/mL DNAse
for 24 hours to ensure DNA removal. The degree of apoptosis, cellular removal, and matrix

25

preservation was assessed using immunochemistry on nerve tissue sections and
fluorescence imaging (Fig 2). Antibodies used to identify apoptosis, cell removal, and tissue
preservation include those against active caspase 3 (Abcam); neurofilament (RT-97, DSHB)
and S100 (Dako); and laminin (Sigma), respectively. Fig. 2A shows immunochemical
staining of a fresh peripheral nerve used as a no treatment control. Figs. 2B and 2C show

30

nerves treated with 5 IJM for 1 day, washed with a hypertonic, and either washed with a
hypertonic solution or treated for 24 hours with DNAse, respectively. Fig. 20 shows staining
of a fresh nerve that was subjected to the same hypertonic and hypotonic washes and
represents the results of not inducing apoptosis prior to washing the tissue. Figs. 2E and 2F
show treatment with higher camptothecin (10 IJM), again for 1 day, and washed similarly to

35

tissue in Figs. 2B and 2C. These images depict 1) apoptosis induction is necessary prior to

9
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washing to effectively remove cellular components and 2) combing apoptosis induction with
washes in non-isotonic solutions achieves cellular removal of peripheral nerve tissue.
Total DNA content was quantified using a Picogreen DNA assay (Life Technologies)
according to manufacturer's instructions. DNA quantification data are shown in Figs. 3 and 4.
5

Washing the tissue without first inducing apoptosis resulted in only a 29.8% reduction of
DNA content compared to fresh nerve. Conversely, inducing apoptosis using 5 or 10 IJM
camptothecin yielded a 71.9 and 57.3% reduction in DNA, respectively. Replacing the
hypotonic wash with DNAse treatment further reduced the DNA content, with 5 and 10 IJM
camptothecin treatment for 1 day resulting in a 95.1 and 95.8% reduction.

10
Example 2:
Peripheral nerves were harvested from Sprague Dawley rats and decellularized
according to an apoptosis-assisted protocol using 10 IJM camptothecin in non-supplemented
media at 3rC for 2 days. Tissue in media without camptothecin was used as a control.
15

Apoptotic agent treatment was succeeded by washes in saline buffered solutions to optimize
cell removal. The degree of apoptosis, cellular removal, and matrix preservation was
assessed using immunochemistry on nerve tissue sections and fluorescence imaging.
Antibodies used to identify apoptosis, cell removal, and tissue preservation include those
against active caspase 3 (Abcam); neurofilament (RT-97, DSH8) and S100 (Dako); and

20

laminin (Sigma), respectively. Apoptosis-mediated DNA fragmentation was assessed using a
terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. Total DNA
content was quantified using a Picogreen DNA assay (Life Technologies) according to
manufacturer's instructions.
Figs. 5A-5C demonstrate fluorescence micrographs of nerve tissue labeled for cell or

25

basal lamina markers. For Figs. 5A and 58, the images are fresh nerve (top half) and
apoptosis decellularized nerve (bottom half). Fig. 5A was labeled for neurons (neurofilament,
green), Schwann cells (S100, red), and nuclei (DAPI, blue). Fig. 58 shows cross-sections of
the basal lamina stained for laminin (red). Fig. 5C shows a representative basal lamina
staining in nerve tissue decellularized according to a conventional detergent-based method.

30

Induction of apoptosis was confirmed in treated nerve tissue by an increase in active
caspase 3, an early mediator of apoptosis. Moreover, TUNEL staining revealed pervasive
DNA fragmentation in treated nerves, indicating late stage apoptosis, as well. Media controls
exhibited neither hallmark of apoptosis. Following induction of apoptosis, cellular proteins
were easily removed using only washes in hypertonic 4X saline buffer while removal of DNA

35

required brief washes in mildly hypotonic 0.5X saline buffer. Using this regimen, a
substantial reduction in cellular and nuclear staining was achieved compared to fresh nerve.
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Notably, the basal lamina microstructure was nearly identical to fresh nerve and was
significantly improved over alternatively processed tissue.
Treatment with camptothecin was observed to be sufficient to elicit aspects of
apoptosis ex vivo, including caspase 3 activation and DNA fragmentation. Moreover,
5

induction of apoptosis was observed to enable extensive removal of cellular and nuclear
components from peripheral nerve tissue using only non-isotonic buffers. Two analogs of
camptothecin are considered safe by the FDA, which bolsters the clinical potential of this
apoptosis-assisted decellularization method. Ultimately, the approach demonstrated here
and described herein can eliminate the need for harsh lysis and chemical steps in

10

conventional protocols and pushes decellularization technology toward achieving 3D, cellfree replicas of native tissue.

Example 3:
Cervical and lumbar segments were removed Yorkshire-Landrace porcine.
15

Each

motion segment was carefully dissected to extract the nucleus pulposus as shown in Figure
7. Nucleus pulposi were decellularized according to an apoptosis-assisted protocol using 10

IJm camptothecin in standard non-supplemented culture media for 24 hours. Control
samples were also processed in parallel without camptothecin. After induction of apoptosis,
samples were washed in a series of hypertonic and hypotonic buffers to remove apoptotic
20

cell bodies (Table 1).
Table 1
Wash Type

Method

Hypertonic

2X PBS 30min, 4X PBS 1Shrs, 2X PBS 30min, 1X PBS 30min

Hypotonic

0.5X PBS 1Shrs, 1X PBS 30min

Hyper-Hypo

2X PBS 30min, 4X PBS 1Shrs, 2X PBS 30min, 1X PBS 30min, 0.5X PBS 6hr,
1X PBS 30min

Hypo-Hyper

0.5X PBS 1Shrs, 1X PBS 30min, 2X PBS 30min, 4X PBS 6hrs, 2X PBS 30min,
1X PBS 30min

Hyper-DNase

2X PBS 30min, 4X PBS 1Shrs, 2X PBS 30min, 1X PBS 30min, 24hrs DNase,
1X PBS 45 mins

No Wash

Fix Immediately after 24hrs in media.

After washes, samples were processed for fixed and stained using DAPI (Thermo Fisher,
01306) to detect removal of cell nuclei, and a chondroitin sulfate proteoglycan (CSPG)
antibody (Sigma, CS035) to examine maintenance of key proteins. Confocal imaging was
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used to assess removal of cell nuclei and maintenance of CSPGs. Results demonstrated in
Figs. 6A-6D suggest the hypertonic wash and the hypertonic-hypotonic wash substantially
remove cell nuclei while maintaining desired CSPGs.
Example 4:

5

Rat sciatic nerve was isolated from Sprague Dawley rats and decellularized using
either standard detergent-based methods or apoptosis induction and tonic wash methods as
detailed in Example 1 above. A rat transection model of nerve injury was performed in Lewis
rats to determine efficacy of apoptosis decellularized samples compared to detergent
decellularized samples, fresh harvested Lewis isograft sciatic nerves, and a sham control

10

group. Briefly, sciatic nerve was transected and 8 mm of sciatic nerve was then removed to
create a 10 mm nerve gap. After transection, one of three samples was implanted via direct
suture to the nerve stumps (detergent, apoptosis, or isograft). Implants and sham controls
were harvested at 4 weeks (n=3) and 8 weeks (n=6) for histological analysis. Tibialis anterior
muscles were also harvested and weighed at 4 and 8 weeks to determine degree or re-

15

innervation of a distal target, an indirect assessment of regeneration.
Results are shown in Fig. 8 and indicate that apoptosis decellularized samples
enhance muscle recovery compared to detergent decellularized samples at both weeks 4
and 8, and are approaching levels of the isograft gold standard treatment.. Throughout the
time course of the study (2,4,6, and 8 weeks), animals were also recorded while walking on

20

a track to analyze alterations in gait (data not shown). Histology was used to assess the
degree of regeneration between groups at both 4 weeks and 8 weeks. (data not shown).
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We claim:
1.

A tissue deceliularization method comprising:
obtaining a tissue sample from a subject to generate an ex vivo tissue

sample;
exposing the ex vivo tissue sample to an apoptotic agent or apoptotic
process; and
washing the ex vivo tissue sample in a hypertonic solution, a hypotonic
solution,

2.

or a hypertonic solution and a hypotonic solution.

The method of claim 1, wherein the tissue sample is a peripheral nerve, a

nucleus pulposus, or a combination thereof.

3.

The method of claim 1, wherein the tissue sample is lung tissue.

4.

The method of claim 1, wherein the apoptotic agent is camptothecin,

staurosporine, doxorubicin, or an analog thereof.

5.

The method of claim 1, wherein the apoptotic process comprises one or more

freeze-thaw cycles.

6.

The method of claim 1, wherein the concentration of the apoptotic agent

ranges from about 5IJM to about 10 IJM.

7.

The method of claim 1, wherein the concentration of the apoptotic agent is

about 10 IJM.

8.

The method of claim 1, wherein the concentration of the apoptotic agent is

about 5 IJM.

9.

The method of claim 1, wherein the ex vivo tissue sample is exposed to the

apoptotic agent for about 2 days.

10.

The method of claim 1, wherein the tissue is washed with a hypertonic

solution.

11.

The method of claim 10, wherein the hypertonic solution is greater than 1X

buffered solution.
13
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12.

The method of claim 10, wherein the hypertonic solution is 4X saline.

13.

The method of claim 1, wherein the tissue is washed with a hypotonic

solution.

14.

The method of claim 13, wherein the hypotonic solution is less than 1X

buffered solution.

15.

The method of claim 13, wherein the hypotonic solution is a 0.5X saline

solution.

16.

The method of claim 13, wherein the concentration the concentration of the

apoptotic agent is about 5 IJM.

17.

The method of claim 16, wherein the apoptotic agent is camptothecin,

staurosporine, doxorubicin, an analog thereof.

18.

The method of anyone of claims 1, 8, or 13-17, further comprising the step of

treating the tissue with DNAse for a period of time ranging from 30 minutes to 24 hours.

19.

The method of claim 1, wherein the step of washing produces an acellular

tissue product.

20.

The method of claim 19, further comprising the step of adding an active agent

to the acellular tissue product.

21.

The method of claim 20, wherein the active agent is selected from the group

consisting of: a stem cell, nucleic acid, amino acid, peptide, polypeptide, antibody, aptamer,
ribozyme, guide sequence for a ribozyme that inhibit translation or transcription of essential
tumor proteins and genes, hormone, immunomodulator, antipyretic, anxiolytic, antipsychotic,
analgesic,

antispasmodic,

anti-inflammatory,

anti-histamine,

anti-infective,

a

chemotherapeutic, or combinations thereof.

22.

An acellular tissue product, where the acellular tissue product is formed by a

method according to anyone of claims 1-17.

14
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The acellular tissue product of claim 22, wherein the method further includes

the step of treating the tissue with DNAse for a period of time ranging from 30 minutes to 24
hours.

24.

The acellular tissue product of claim 22, further comprising an active agent.

25.

The acellular tissue product of claim 23, wherein the active agent is selected

from the group consisting of: a stem cell, nucleic acid, amino acid, peptide, polypeptide,
antibody, aptamer, ribozyme, guide sequence for a ribozyme that inhibit translation or
transcription of essential tumor proteins and genes, hormone, immunomodulator, antipyretic,
anxiolytic, antipsychotic, analgesic, antispasmodic, anti-inflammatory, anti-histamine, antiinfective, a chemotherapeutic, or a combinations thereof.

26.

The acellular tissue product of anyone of claims 22-25, wherein the acellular

tissue product is formulated for injection.

27.

A method comprising:

administering an acellular tissue product as in anyone of claims 19-21 or 22-26 to a
subject in need thereof.

28.

The method of claim 27, where the subject in need thereof has a spinal injury

or disease, intervertebral disc degeneration, disease or trauma of the lungs or liver, or
volumetric muscle loss,

peripheral nerve injury,

amputation or spinal degradation,

osteoarthritis of the hip or knee, volumetric muscle loss, cirrhosis of the liver, or otherwise
requires partial or total organ replacement.

15

WO 2017/011653

1000

1/8

PCT/US2016/042273

~

1010

-

Obtain tissue sample

1
1020-

Induce widespread apoptosis in tissue
sample

\I

1030 -

Remove apoptotic bodies in mild
hypertonic buffered solutions and/or
mild hypotonic buffered solutions
'v

1040 -

Optional DNase treatment

\I

acellular tissue

FIG. 1

WO 2017/011653

t/)

...
oa..
r::::

o
o

2/8

PCT/US2016/042273

WO 2017/011653

PCT/US2016/042273

3/8

1800
1600

-E
--

1400

C)

C)

--

1200

r:::::
r:::::

1000

CI)

r:::::

0

800

«
Z

600

U

C

400
200
0

Fresh
Nerve

Fresh
+Wash

5 !-1M

10 !-1M

5 !-1M

10 !-1M

1 DIV

1 DIV

1 DIV

1 DIV

FIG. 3

ng/mg

1500.0

1052.7

420.9

640.0

73.4

63.2

% Removal

--

29.8

71.9

57.3

~~5,"~

,~s, ~

FIG.4

,. ,.'",,-...~

......

WO 2017/011653

4/8

u

lot)

•

-

(!)
LL.

OJ

lot)

•

-

(!)
LL.

<C
lot)
•

-

(!)
LL.

PCT/US2016/042273

WO 2017/011653

5/8

PCT/US2016/042273

WO 2017/011653

6/8

PCT/US2016/042273

•

-

(!)
LL.

c
0

........

co

0

CJ)
CJ)

::J

CJ)

0

c..
::J

0...

CJ)

::J

Q.)

()

::J

Z

<C
.......

•

-

(!)
LL.

WO 2017/011653

PCT/US2016/042273

7/8

+-'

Vl
Vl

C

0)

b.O

!o....

0)
+-'
0)

0

•

+-'

0

\+0-

ro
!o....

+-'

0..

0

b.O

«

Vl

0

0..

\"""",,'\
~

rnJ

~

~. . . . . . . . .J

-u

C1J
V)

::::s
~

~

*

'-

0

-'-

....c:
C1J

<C

0)
0)

;:
00

C1J

E
-I-

..j...I

c

0-

0

a...

'C1J

Q)

>
----ta 0
..c ..c:
-1lO
I- -C1J
'+-

E

V)

....

0

>
>
0

l~

0)
0)

;:
o::::t

S

'C1J
U

C1J

a:::

0
0

0
0

Lf)
0

0

0
0

o::::t

M

0

0

0

0
0
N
0

0
0

~

0

0

0

(pa.JnfU!/lo.flUOJ)
O!leH l4~!aM alJsnll\l

0
0
0
0

CO
•

-

(!)
LL.

WO 2017/011653

PCT/US2016/042273

8/8

c:
0

tn'"
._
co
tn

N

U

o 'i:
...
co en•
c.o :::l (!)
c.=
<c B LL.

-

Q)

C

.......
~
... enOJ
....
E
...co
Q)

.£:

~

c:

Q)

•

(!)
LL.

....Q)

I-

<C

en
•

-

(!)
LL.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 16142273

A.

CLASSIFICATION OF SUBJECT MATTER
A61K 35/32, A61K 35/36, A61K 35/34 (2016.01)

IPC(8) CPC -

A61L 27/3641, A61L 2430/40, A61L 27/3683, A61L 27/60
According to International Patent Classification (lPC) or to both national classification and IPC
B.

FIELDS SEARCHED

Minimum documentation searched (classification ~stem followed by classification symbols)
IPC (8) - A61K 35/32, A61K 35/36, A61K 35/34 ( 016.01)
CPC - A61L 27/3641, A61L 2430/40, A61L 27/3683, A61L 27/60

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
USPC - 424/548,424/574,424/569

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
PatBase, Google Patent, Google Scholar
Terms used: decellularization tissue acellular washing hypotonic hypertonic apoptotic agent apoptosis camptothecin staurosporin
doxorubicin saline dnase deoxyribonuclease endonuclease freeze thaw cryo lung peripheral nelVe nucleus pulposus

C.

DOCUMENTS CONSIDERED TO BE RELEVANT
Citation of document, with indication, where appropriate, of the relevant passages

Category·

Relevant to claim No.

Y

US 2003/0219417 A 1 (Wolfinbarger, JR) 27 November 2003 (27.11.2003) para [0012]; [0039][0041]

1-25

Y

US 2011/0045045 A1 (Corti ella et al.) 24 February 2011 (24.02.2011) para [0032]; [0036]

1-3,5,10-15,18-25

Bourgine et aI., 'Tissue decellularization by activation of programmed cell death', Biomaterials
34 (2013) 6099-6108, whole document, especially pg 6106, para 2

1,4,6-9, 13, 16-17

Y

US 2015/0037436 A1 (Huang et al.) 05 February 2015 (05.02.2015) para [0011]-[0012]

2

Y

US 5,968,824 A (Spruce et al.) 19 October 1999 (19.10.1999) col 14,In 26-27; col 22,In 52-53,
57;

4,6-9,13,16-17

A

US 2008/0306610 A1 (Wang et al.) 11 December 2008 (11.12.2008) whole document,
especially para [0006]; [0022]; [0034]

1,10-15

A

US 201210259415 A1 (Van Dyke et al.) 11 October 2012 (11.10.2012) whole document,
especially para [0011]; [0014]; [0041]

1,10-15

A

WO 1998/031787 A1 (EISAI CO LTD) 23 July 1998 (23.07.1998) whole document

4,6-9, 16-17

A

WO 1998/045429 A2 (NOVARTIS AG) 15 October 1998 (15.10.1998) whole document

4,6-9, 16-17

Y

D

-

Further documents are listed in the continuation of Box C.

•

D

Special categories of cited documents:
"T'
"A" document defining the general state of the art which is not considered
to be of particular relevance
"E" earlier application or patent but published on or after the international "X"
filing date
"L" document which may throw doubts on priority claim(s) or which is
cited to establish the I?ublication date of another citation or other
"Y"
special reason (as speCified)
"0" document referring to an oral disclosure, use, exhibition or other
means
"P" document published prior to the international filing date but later than "&"
the priority date claimed
Date of the actual completion of the international search
26 August 2016
Name and mailing address of the ISAIUS
Mail Stop PCT, Attn: ISAlUS, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450
Facsimile No. 571-273-8300
Form PCT/ISA/2 IO (second sheet) (January 2015)

later document published after the international filing date 0'!eriority
date and not in conflict with the ap~lication but cited to un erstand
the principle or theory underlying t e invention
document of particular relevance; the claimed invention cannot be
considered novel or cannot be considered to involve an inventive
step when the document is taken alone
document of particular relevance; the claimed invention cannot be
considered to involve an inventive step when the document is
combined with one or more other such documents, such combination
being obvious to a person skilled in the art
document member of the same patent family

Date of mailing of the international search report

30 SEP 2016
Authorized officer:
Lee W. Young
PCT HBlpdBSk: 571-272-4300
PCT osp: 571-272-7n4

INTERNATIONAL SEARCH REPORT

International application No.
peT/US 16/42273

Box No. II

Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
I.

0

2.

0

3.

IZI

Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an
extent that no meaningful international search can be carried out, specifically:

Claims Nos.: 26-28
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III

Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found mUltiple inventions in this international application, as follows:

1.0

3.

0
0

4.

0

2.

As all required additional search fees were timely paid by the applicant, this international search report covers all searchable
claims.
As all searchable claims could be searched without effort justifYing additional fees, this Authority did not invite payment of
additional fees.
As only some of the required additional search fees were timely paid by the applicant, this international search report covers
only those claims for which fees were paid, specifically claims Nos.:

No required additional search fees were timely paid by the applicant. Consequently, this international search report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

o

o
o

The additional search fees were accompanied by the applicant's protest and, where applicable, the
payment of a protest fee.
The additional search fees were accompanied by the applicant's protest but the applicable protest
fee was not paid within the time limit specified in the invitation.
No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (2» (January 2015)

